Gemcitabine-induced thrombotic microangiopathy: A systematic review

Nephrology Dialysis Transplantation

Volumn 21, Issue 11, 2006, Pages 3038-3045

  Izzedine, Hassane ^a   Isnard Bagnis, Corinne ^a   Launay Vacher, Vincent ^a   Mercadal, Lucille ^a   Tostivint, Isabelle ^a   Rixe, Olivier ^a   Brocheriou, Isabelle ^a   Bourry, Edward ^a   Karie, Svetlana ^a   Saeb, Samir ^a   Casimir, Nadine ^a   Billemont, Bertrand ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Gemcitabine; Haemolytic uraemic syndrome; Thrombotic microangiopathy

Indexed keywords

ANTIHYPERTENSIVE AGENT; CORTICOSTEROID; CREATININE; DOXYCYCLINE; FIBRINOGEN; FLUOROURACIL; FUROSEMIDE; GEMCITABINE; HAPTOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; NAVELBINE; OXALIPLATIN; PLATINUM COMPLEX; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ADULT; AGED; BILE DUCT CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL TRIAL; CREATININE CLEARANCE; DISEASE EXACERBATION; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; HEMATURIA; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FAILURE; LIVER CARCINOMA; LUNG ADENOCARCINOMA; LUNG EDEMA; LUNG RESECTION; LUNG SMALL CELL CANCER; MASTECTOMY; NONHODGKIN LYMPHOMA; OVARY ADENOCARCINOMA; PANCREAS CANCER; PATIENT SELECTION; PERIPHERAL EDEMA; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; INCIDENCE; KIDNEY; MICROCIRCULATION; RETROSPECTIVE STUDIES; SYNDROME; THROMBOSIS;

EID: 33749996482     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl507     Document Type: Review

References (47)

1. Casper ES, Green MR, Kelsen DP et al. Phase II trial of gemcitabine (2,20-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34
2. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999; 85: 2023-2032
3. Humphreys BD, Sharman JP, Henderson JM et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004; 100: 2664-2670
4. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis 2002; 40: E16
5. Brodowicz T, Breitender S, Wiltschke C, Zielinski CC. Gemcitabine-induced hemolytic uremic syndrome: A case report. J Natl Cancer Inst 1997; 89: 1895-1896
6. Gordon LI, Kwaan HC. Cancer and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997; 34: 140-147
7. Serke S, Riess H, Oettle H, Huhn D. Elevated reticulocyte count - a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: A case report. Br J Cancer 1999; 79: 1519-1521
8. Flombaum CD. Gemcitabine nephrotoxicity and the Hemolytic Uremic Syndrome (HUS): Report of 29 cases from a single institution. SA-PO1008. ASN 2005
9. Saif MW, Sellers S, Russo S. Gemcitabine-related radiation recall in a patient with pancreatic cancer. Anticancer Drugs 2006; 17: 107-111
10. Muller S, Schutt P, Bojko P et al. Hemolytic uremic syndrome following prolonged gemcitabine therapy: Report of four cases from a single institution. Ann Hematol 2005; 84: 110-114
11. Choi M, Woywodt A, Gobel U, Schneider W, Kettritz R. Haemolytic uraemic syndrome after gemcitabine treatment for pancreatic carcinoma. Nephrol Dial Transplant 1999; 14: 2523-2524
12. Ruiz I, Del Valle J, Gomez A. Gemcitabine and haemolyticuraemic syndrome. Ann Oncol 2004; 15: 1575-1576
13. Nackaerts K, Daenen M, Vansteenkiste J, Vandevelde A, Van Bleyenbergh P, Demedts M. Hemolytic-uremic syndrome caused by gemcitabine. Ann Oncol 1998; 9: 1355
14. Lewin SN, Mutch DG, Whitcomb BP, Liapis H, Herzog TJ. Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol 2005; 97: 228-233
15. Venat-Bouvet L, Ly K, Szelag JC et al. Thrombotic microangiopathy and digital necrosis: Two unrecognized toxicities of gemcitabine. Anticancer Drugs 2003; 14: 829-832
16. Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolyticuremic syndrome due to gemcitabine. Anticancer Drugs 2003; 14: 665-668
17. Eckel F, Lersch C, Erdmann J, Schmidt B, Schulte-Frohlinde E. A 42-year-old patient with the hemolytic-uremic syndrome under gemcitabine therapy for an adenocarcinoma of the liver. The hemolytic-uremic syndrome and gemcitabine. Z Gastroenterol 2000; 38: 593-596
18. Desrame J, Duvic C, Bredin C et al. Hemolytic uremic syndrome as a complication of gemcitabine treatment: Report of six cases and review of the literature. Rev Med Interne 2005; 26: 179-188
19. Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis 1999; 33: 555-562
20. Teixeira L, Debourdeau P, Zammit C, Estival JL, Pavic M, Colle B. Gemcitabine-induced thrombotic microangiopathy. Presse Med 2002; 31: 740-742
21. Citarrella P, Gebbia V, Teresi M et al. Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: A case report. Anticancer Res 2002; 22: 1183-1185
22. Dilhuydy MS, Delclaux C, Pariente A, De Precigout V, Aparicio M. Hemolytic-uremic syndrome complicating a longterm treatment with gemcitabine. Report of a case and review of the literature. Rev Med Interne 2002; 23: 189-192
23. Gross M, Hiesse C, Kriaa F, Goldwasser F. Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine. Anticancer Drugs 1999; 10: 533-536
24. Lhotta K, Kuhr T, Rumpelt HJ, Woll E, Thaler J, Konig P. Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy. Am J Nephrol 1999; 19: 590-593
25. Klapdor R, Seutter E, Lang-Polckow EM, Reichle H, Hinrichs A. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers. Anticancer Res 1999; 19: 2459-2469
26. van Meerbeeck JP, Baas P, Debruyne C et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999; 85: 2577-2582
27. Fisher DC, Sherrill GB, Hussein A et al. Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Bone Marrow Transplant 1996; 18: 193-198
28. Schieppati A, Ruggenenti P, Cornejo RP et al. Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome. J Am Soc Nephrol 1992; 2: 1640-1644
29. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23: 32-35
30. Pham PT, Peng A, Wilkinson AH et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 2000; 36: 844-850
31. Morel-Maroger L, Kanfer A, Solez K, Sraer JD, Richet G. Prognostic importance of vascular lesions in acute renal failure with microangiopathic hemolytic anemia (hemolytic-uremic syndrome): clinicopathologic study in 20 adults. Kidney Int 1979; 15: 548-558
32. Melnyk AM, Solez K, Kjellstrand CM. Adult hemolytic-uremic syndrome. A review of 37 cases. Arch Intern Med 1995; 155: 2077-2084
33. Lohrmann HP, Adam W, Heymer B, Kubanek B. Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med 1973; 79: 368-375
34. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325: 398-403
35. Neild GH. Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura: pathophysiology and treatment. Kidney Int 1998; 64: S45-S49
36. Allford SL, Hunt BJ, Rose P, Machin SJ. Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556-573
37. Fakhouri F, Vernant JP, Veyradier A et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: A study of 11 cases. Blood 2005; 106: 1932-1937
38. Ahmad A, Aggarwal A, Sharma D et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004; 77: 171-176
39. Izzedine H, Launay-Vacher V, Mercadal L, Vernant JP, Deray G. Doxycycline, gastrointestinal bleeding, and thrombotic microangiopathy. Am J Hematol 2004; 77: 319
40. Rieger M, Mannucci PM, Kremer Hovinga JA et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262-1267
41. Furlan M, Robles R, Galbusera M et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584
42. Moake, JL. Moschcowitz, multimers, and metalloprotease. N Engl J Med 1998; 339: 1629-1631
43. van der Heijden M, Ackland SP, Deveridge S. Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy-a case report and review of the literature. Acta Oncol 1998; 37: 107-109
44. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600
45. Raife TJ, Lager DJ. Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects. Mayo Clin Proc 2002; 77: 323-328
46. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Soderland C, Ahn YS. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol 2003; 123: 896-902
47. Ballermann BJ. Endothelial cell activation. Kidney Int 1998; 53: 1810-1826